Moving from Mounjaro 5mg to 7.5mg: the evidence behind the step up

What the clinical evidence shows about higher doses and greater weight loss

The SURMOUNT-1 trial, published in the New England Journal of Medicine, randomised 2,539 adults with obesity across three active dose arms: 5mg, 10mg and 15mg, each taken weekly. Average weight reduction at 72 weeks was roughly 15% at 5mg, around 19.5% at 10mg, and approximately 20–21% at 15mg. That gradient is the key point for anyone approaching the 5mg to 7.5mg Mounjaro transition: the higher doses consistently produced greater loss, and most of the additional benefit accumulated in the dose range above 5mg.

7.5mg sits squarely in that ascending range. It is not a maintenance dose for most people (the titration continues toward 10mg, 12.5mg and 15mg if tolerated) but it is the point at which many patients begin to feel the medicine working more noticeably. The NHS tirzepatide page describes the six available UK strengths and confirms that treatment is titrated gradually by a prescriber, with each step designed to give the body time to adapt before the next increase.

SURMOUNT-1 did not test 7.5mg as a standalone arm, so direct figures for that precise dose come from the SmPC and the broader titration rationale rather than a separate group in the trial. What the data do confirm, clearly, is that staying at 5mg long-term delivers less weight reduction than moving through the schedule, and for those who want to understand where the schedule ultimately leads, our tirzepatide 80 mg page explains what research into higher cumulative doses looks like. The step to 7.5mg is part of getting there.

Why the dose schedule is designed the way it is, and what 5mg is actually for

There is a reasonable amount of anxiety that comes with dose increases, which is understandable. The question most people are really asking is: will it make the side effects come back?

The Mounjaro titration schedule (2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg) exists primarily to manage tolerability. The starter doses of 2.5mg and 5mg are not primarily therapeutic doses; their job is to let the gastrointestinal system adjust to a dual GIP and GLP-1 receptor agonist before the dose reaches the range where the bulk of weight loss happens. By the time someone reaches the 5mg pen and has tolerated it for four weeks, the gut is considerably better adapted than it was at the start.

That said, increasing to 7.5mg can temporarily stir up nausea, loose stools or reduced appetite again. This is normal and reflects the body recalibrating to a higher concentration of the medicine. For most people these effects are milder than they were at the very beginning and pass within days to two weeks. If they persist or are severe, that is a reason to contact your clinical team, not to manage the change alone. You can read more about what to expect on the 7.5mg dose specifically, including common experiences at that level.

The SmPC (the summary of product characteristics, the definitive clinical reference for Mounjaro) sets out the full schedule and the four-week minimum at each dose. The Patient Information Leaflet included with every pen covers missed doses and storage. These are the authoritative sources for your specific situation, your prescriber works from them directly.

Practical considerations when your prescription moves to 7.5mg

The transition from 5mg to 7.5mg Mounjaro means switching to a new pen. The two strengths are not adjustable on the same device, each pen delivers a fixed dose. It is worth confirming with your pharmacy which pen you are being dispensed before you use it; the pen label and the dose printed on it should match your prescription.

Injection technique does not change between doses. The same three sites apply (abdomen, thigh or upper arm) and rotating the site each week remains the recommendation per the licensed guidance. Storage is the same: refrigerated between 2–8°C, keeping the pen away from the freezer compartment. The exact permitted room-temperature window if you are travelling is set out in the Patient Information Leaflet; refer there rather than to any general figure, since the window varies depending on circumstance.

If you are tracking your own progress, it is worth knowing that meaningful weight change often becomes more visible in the weeks following the 7.5mg step and beyond. Some people describe this as the dose at which the medicine starts to feel qualitatively different, appetite suppression becomes steadier and eating behaviours shift more noticeably. Curious about how the dosing picture compares between the two specific strengths? The 5mg versus 7.5mg comparison covers the key differences in more detail.

For context on what private treatment costs across the dose range, the Mounjaro pricing page sets out the market picture honestly, including what to expect as doses increase. As a prescription medicine, the cost of private treatment should be weighed against the value of proper clinical oversight, not against the cheapest listing you find online.

How your prescriber decides you are ready to move up

At nume, no dose change goes through without a clinical review. Before each repeat order, a GPhC-registered Independent Prescriber reads your update (a real clinician, not an automated system) and assesses whether the move to 7.5mg is appropriate based on your tolerability, weight progress and any reported side effects. Evidence of your current treatment is required for dose increases; this is not a formality but part of the safety infrastructure that distinguishes a regulated prescribing service from the unverified sellers the MHRA has repeatedly warned about.

NICE's appraisal of tirzepatide, TA1026, notes that if less than 5% weight loss is achieved after six months at the highest tolerated dose, continuing treatment should be reconsidered. This gives you a sense of the clinical standard being applied: progress is monitored, not assumed. Moving from 5mg to 7.5mg is usually a straightforward step when tolerability is confirmed, but the prescriber's job is to make that call with your full picture in front of them.

If you are on a different titration path (perhaps exploring the 2.5mg to 5mg step, or looking ahead to higher strengths) each transition follows the same logic: four weeks minimum at each dose, tolerability assessed, progress reviewed, and the next step taken only when clinically appropriate. That is how the medicine is designed to work. If you would like a prescriber to review your suitability, checking your eligibility takes a few minutes and costs nothing.